🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against superbug strains of the pathogen, according to scientists.

An International Challenge

The sexually transmitted infection are escalating worldwide, with estimates suggesting over 82 million new cases annually. Notably increased rates are seen in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary step in the context of growing infection rates, escalating drug resistance and the extremely scarce available drugs at this time.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to significant complications, including infertility. Researchers anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization marks a major breakthrough in the management of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Results and Global Access

According to results detailed in a major medical journal, the new drug cured over nine in ten of cases of the STI. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The research involved over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Clinicians treating patients have voiced hope. Having a single-dose, oral treatment such as this is described as a "game-changer" for managing the epidemic. This is viewed as vital to lessen the impact of the disease for patients and to prevent the spread of untreatable gonorrhoea globally.